Clinical and morphological analysis and evaluation of treatment results of patients with primary testicular diffuse large B-cell lymphoma

Introduction. Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is characterized by an aggressive course and a high relapse rate when using standard therapy protocols. A feature of PT-DLBCL is its high tropism for central nervous system damage.

Aim: to compare the treatment outcomes of patients with PT-DLBCL treated with known protocols and according to the “PTL2022” protocol.

Materials and Methods. From 2006 to 2025, 54 patients with PT-DLBCL were included in the analysis: 12 patients in the prospective group and 42 patients in the retrospective control group.

Results. CNS involvement at the onset of PT-DLBCL in the prospective group was present in 60 % of patients, in the retrospective group the frequency of CNS involvement is unknown. In the entire group of all 54 patients with PT-DLBCL, event-free survival (EFS) and overall survival (OS) were 20 % and 29 %, respectively. In the retrospective group, EFS was 17%, in the prospective group 90 %, OS — 28 % and 90 %, respectively.

Conclusion. The “PTL-2022” protocol is reproducible, effective and safe in different age groups of patients. An improvement of treatment outcomes with the “PTL-2022” protocol was established in the high-risk group.

1. Medina A.A., Álvaroa J.L., Irene Carretero del Barriob I.L.G., et al. Primary testicular lymphoma: Clinical characteristics and oncological outcomes. Curr Urol. 2020;17(2):130–4. DOI: 0.1097/CU9.0000000000000137.

2. Lee Y., Yoon S.E., Cho J., et al. Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma. Cancer Manag Res. 2023;15:463–74. DOI: 10.2147/CMAR.S407837.

3. Qualls D., Abramson J.S. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 2019;104(1):25–34. DOI: 10.3324/haematol.2018.195834.

4. Koroleva D.A., Zvonkov E.E., Shchetsova O.O., et al. Biopsy-free diagnostics of primary diffuse large B-cell lymphoma of the central nervous system. Gematologiya I Transfusiologiya. 2024;69(3):368–83 (In Russian). DOI: 10.35754/0234-5730-2024-69-3-368-383.

5. Ferreri J.M., Stathis A., Botto B., et al. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. Blood Adv. 2024;8(6):1541–9. DOI: 10.1182/bloodadvances.2023011251.

6. Zucca E., Conconi A., Mughal T.I., et al. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20–7. DOI: 10.1200/JCO.2003.11.141.

7. Jackson S.M., Montessori G.A. Malignant lymphoma of the testis: review of 17 cases in British Columbia with survival related tp pathological subclassifi cation. J Urol. 1980;123(6):881–3. DOI: 10.1016/S0022-5347(17)56175-3.

8. Zelenetz A.D., Gordon L.I., Abramson J.S., et al. B-Cell Lymphomas. NCCN Clin Pract Guidel Oncol. 2025;3.

9. Parovichnikova E.N., Poddubnaya I.V., Levkoskiy O.V., et al. Aggressive non-follicular lymphomas — diffuse large B-cell lymphoma, high-grade B-cell lymphoma with c-MYC and BCL2/BCL6 gene rearrangement, primary mediastinal B-cell lymphoma, gray zone mediastinal lymphoma. Clinical guidelines. 2024 (In Russian).

10. Nesterova E.S., Mangasarova Ya.K., Baryakh E.A., et al. Experience with high-dose chemotherapy in patients with diffuse large B-cell lymphoma with testicular involvement. Therapevticheskiy arkhive. 2014;7:59–67 (In Russian).

11. Liu Y., Zhang Q., Lv F., et al. Lenalidomide combined with R-CHOP (R2-CHOP ) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial. Blood Cancer J. 2025;15(24):3–6. DOI: 10.1038/s41408-025-01229-5.

12. Johnson P.W.M., Balasubramanian S., Hodkinson B., et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023;7(10):2008–17. DOI: 10.1182/bloodadvances.2022009389.

13. Neelapu S.S., Jacobson C.A., Ghobadi A., et al. Five-year follow-up of ZUMA1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307–15. DOI: 10.1182/blood.2022018893.

14. Chavez J.C., Dickinson M., Munoz J., et al. Three-year follow-up analysis of fi rst-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA12 study. Blood. 2025;145(20):2303–11. DOI: 10.1182/blood.2024027347.

15. Farooq U., Meerten T. Van, Reagan P.M., et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386:640– 54. DOI: 10.1056/NEJMoa2116133.

16. Gerhard G.M., Keudell G. Von. Bispecifi c antibody therapy for lymphoma. Best Pract Res Clin Haematol. 2025;37(4):101598. DOI: 10.1016/j.beha.2025.101598.

17. Wirsching H.-G., Weller M., Balabanov S., et al. Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. Cancer. 2021;13(3073):1– 13. DOI: 10.3390/cancers13123073.

18. Conroy T., Hammel P., Hebbar M. Maintenance lenalidomide in primary CNS lymphoma. Ann Oncol. 2019;30(8):1397–8. DOI: 10.1093/annonc/mdz142.

19. Cook M.R., Dorris C.S., Makambi K.H., et al. Toxicity and ef fi cacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7(1):32–9. DOI: 10.1182/bloodadvances.2022008525.

20. Houillier C., Choquet S. CAR T-cell Therapy for Central Nervous System Lymphoma. Curr Oncol Rep. 2024;26:1521–9. DOI: 10.1007/s11912-024-01609-3.

21. Aquilanti E., Herrity E., Nayak L. Novel Therapies for Primary Central Nervous System Lymphomas. Curr Neurol Neurosci Rep. 2024;24(12):621–9. DOI: 10.1007/s11910-024-01376-5.

22. Roschewski M., Hodson D.J. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy. Haematologica. 2024;(February):388–400. DOI: 10.3324/haematol.2021.278613.

23. Roemeling C. Von, Ferreri A.J.M., Soussain C., et al. Targets and treatments in primary CNS lymphoma. Leuk Lymphoma. 2024;65(8):1055–67. DOI: 10.1080/10428194.2024.2342560.

24. King R.L., Goodlad J.R., Calaminici M., et al. Lymphomas arising in immuneprivileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020;476:647–65. DOI: 10.1007/s00428-019-02698-3.

25. Zvonkov E.E., Koroleva D.A., Gabeeva N.G., et al. High-dose chemotherapy of primary diffuse large B-cell lymphoma of the central nervous system. Interim results of the CNS-2015 protocol. Hematology and Transfusiology. 2019;64(4):447–61 (In Russian). DOI: 10.35754/0234-5730-2019-64-4-447-461.

26. Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the Committee on Hodgkin’s Disease Staging Classifi cation. Cancer Res. 1971;31(11):1860–1.

27. Cheah C.Y., Wirth A., Seymour J.F. Primary testicular lymphoma. Blood. 2014;123(4):486–93. DOI: 10.1182/blood-2013-10-530659.

28. Tumyan G.S., Sorokin E.N., Kovrigin A.M., et al. Diffuse large B-cell lymphoma with primary localization in the testicle. Klinicheskaya oncogematologiya. 2008;1(3):206–10 (In Russian).

29. Sotnikova O.P., Sorokin E.N., Poddubnaya I.V. Primary non-Hodgkin’s lymphomas of the testicle. Oncourology. 2012;1:88–93 (In Russian).

30. Lelyavin K.B., Taranenko A.V., Bryukhanov V.G. Diffuse large B-cell lymphoma of the testis. Clinical lecture and observation from practice. ACTA Biomed Sci. 2023;8(5):81–91 (In Russian). DOI: 10.29413/ABS.2023-8.5.8.

31. Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classi fi cation of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;(May). DOI: 10.1038/s41375-022-01620-2.

32. Wang L., Guo M., Hou S. Advances in primary large B-cell lymphoma of. Front Immunol. 2025;1–16. DOI: 10.3389/fimmu.2025.1533444.

33. Guo D., Hong L. The Mutation of BTG2 Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. J of Infl ammation Res. 2022;15:1757–69. DOI: 10.2147/JIR.S341355.

34. Xu-Monette Z.Y., Jeffrey Medeiros L., Li Y., et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16):3668–83. DOI: 10.1182/blood-2011-11-366062.

35. Zhang J., Zhang Y., Luo C. Clinical, Pathological and Immunohistochemical Characteristics of Patients with Primary Testicular Lymphoma Undergoing Orchiectomy: A Systematic Review and Meta-Analysis. Arch Esp Urol. 2024;77(5):505– 16. DOI: 10.56434/j.arch.esp.urol.20247705.70.

36. Chapuy B., Roemer M.G.M., Stewart C., et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81. DOI: 10.1182/blood-2015-10-673236.

37. International Non-Hodgkin’s Lymphoma Prognostic Factors Project Shipp M.A. A Predictive model for aggressive non-Hodgkins lymphoma. New Engl J Med. 1993;329:987–94. DOI: 10.1056/NEJM199309303291402.

38. Yang S., Chang W., Zhang B., et al. What factors are associated with the prognosis of primary testicular diffuse large B-cell lymphoma? A study based on the SEER database. J Cancer Res Clin Oncol. 2023;149(12):10269–78. DOI: 10.1007/s00432-023-04907-8.

39. Ma R.Z., Tian L., Tao L.Y., et al. The survival and prognostic factors of primary testicular lymphoma: two decade single center experience. Asian J Androl. 2018;20:615–20. DOI: 10.4103/aja.aja.

40. Ansell S.M., Armitage J.O. Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy. JMCP. 2012;87(6):571–80. DOI: 10.1016/j.mayocp.2012.03.006.

41. Zhong Y., Tan G., Plattel W.J., et al. Detection of Cell Free Tumor DNA in Plasma of Patients with Large B-Cell Lymphoma of the Sanctuary Sites By Digital Droplet PCR. Blood. 2022;140:9516–7. DOI: 10.1182/blood-2022-166357.

42. Ping N., Qu C., Bay L. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B- cell lymphoma with central nervous system progression. Leuk Lymphoma. 2019;60(11):2814–6.

43. Godfrey J.K., Gao L., Shouse G., et al. Glofi tamab stimulates immune cell infi ltration of CNS tumors and induces clinical responses in secondary CNS lymphoma. Blood. 2024 , 25;144(4):457–61. DOI: 10.1182/blood.2024024168.